COMP <GO>
ALHC vs LLY // NET PROFIT MARGIN
Alignment Healthcare Inc. (NASDAQ) VS. Eli Lilly and Company (NYSE) • 15-METRIC TALLY: ALHC 2
— LLY 9
▲ NET PROFIT MARGIN LEADER: LLY
LAST: $8.06 (-1.47%) • MKT CAP: $1.67B
net-margins
0.00%
LAST: $1,373.70 (+6.63%) • MKT CAP: $1.29T
net-margins
31.90%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ALHC VS. LLY)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | ALHC | LLY | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | 83.64% | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 13.90% | 32.36% | -18.46 | LLY | /roic <GO> |
| EV/EBITDA & P/E Valuation | 37.8x | 36.4x | +1.38 | LLY | /valuation <GO> |
| Free Cash Flow Yield | 6.77% | 2.30% | +4.47 | ALHC | /fcf-yield <GO> |
| Operating Margin | 0.40% | 40.21% | -39.81 | LLY | /operating-margins <GO> |
| Net Profit Margin ACTIVE | 0.00% | 31.90% | -31.90 | LLY | /net-margins <GO> |
| Revenue Growth (YoY) | 46.10% | 45.51% | +0.59 | ALHC | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.49% | -0.49 | LLY | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 4.00 | 9.29 | -5.29 | LLY | /balance-sheet <GO> |
| Piotroski F-Score Quality | 6/9 | 9/9 | -3.00 | LLY | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | 6.77% | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 31.6 | 66.6 | -34.97 | LLY | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 0.51 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 26.3x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $1.67B | $1.29T | -$1.29T | LLY | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | ALHC REV | LLY REV | ALHC GROSS % | LLY GROSS % | ALHC FCF | LLY FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $3.95B | $65.18B | — | 83.0% | $113.1M | $16.81B |
| FY 2024 | $2.70B | $45.04B | — | 81.3% | -$6.6M | $8.82B |
| FY 2023 | $1.80B | $34.12B | — | 79.3% | -$59.2M | $4.24B |
| FY 2022 | — | $28.54B | — | 76.8% | — | $7.59B |
| FY 2021 | — | $28.32B | — | 74.2% | — | $7.37B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ALHC // BETA —
LLY // BETA 0.51